Geron Corporation
NASDAQ:GERNBiotechnology
+$0.05 today
- Market cap
- $638.38M
- Beta
- 0.60
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.10
Volume 34.97M
Average 16.28M
GERN Long-term Investments
Investments the company intends to hold for more than a year.
Geron CorporationNASDAQ: GERN
Long-term Investments · Q1 FY2026 · quarter ended Mar 2026
Long-term investments falls 54.6% from a year ago
Long-term investments stood at $26.69M at the end of Q1 FY2026, down 54.6% from a year earlier and down 35.4% from the prior quarter.
Context
- Long-term investments amounted to 5.0% of total assets at the end of Q1 FY2026, down 5.5 pp from a year earlier.
- Long-term investments increased in 2 of the last 3 fiscal years.
What to watch
Whether long-term investments keeps falling in the next quarterly balance sheet after a -54.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Long-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 41.29M USD
- Year-over-year change
- -56.3%
- 4-year CAGR
- +9.6%
| Period | Period end | Long-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 41.29M | -56.3% |
| FY2024 | 2024-12-31 | 94.52M | +118.3% |
| FY2023 | 2023-12-31 | 43.3M | — |
| FY2022 | 2022-12-31 | 0 | -100.0% |
| FY2021 | 2021-12-31 | 28.65M | — |
Long-term Investments vs competitors
How GERN compares with its peers on the latest reported figures
- GERN's Mar 2026 long-term investments of $26.69M is the 3rd highest of the 8 companies compared; the peer median is $0.
- Its year-over-year change of -54.6% is the 3rd highest of 4, against a peer median of +249.8%.
- Long-term investments amounts to 5.0% of total assets for GERN, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $104.39M | +684.1% | -28.9% | 1.3% | |
| Mar 2026 | $82.17M | +249.8% | -64.3% | 25.2% | |
| Mar 2026 | $26.69M | -54.6% | — | 5.0% | |
COAGHemab Therapeutics Holdings, Inc. Common Stock | Jun 2026 | $0 | — | — | 0.0% |
| Sep 2026 | $0 | — | — | 0.0% | |
DMRADamora Therapeutics, Inc. | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Jun 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding GERN) | $0 | +249.8% | -46.6% | 0.0% | |
Competitors are the stored peer set for GERN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 34.87M | 56.85M | 70.02M | 79.02M | 79.44M |
| Short-term Investments | 148.85M | 115.9M | 263.68M | 327.55M | 280.36M |
| Net Receivables | 1.76M | 3.14M | 1.66M | 38.8M | 39.23M |
| Inventory | 0 | 0 | 0 | 38.71M | 0 |
| Other Current Assets | 364K | 4.36M | 5.99M | 6.91M | 121.25M |
| Total Current Assets | 187.21M | 180.25M | 341.35M | 490.99M | 520.27M |
| Property, Plant & Equipment (Net) | 5.38M | 4.94M | 4.73M | 4.19M | 884K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 28.65M | 0 | 43.3M | 94.52M | 41.29M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 4.8M | 5.39M | 4.7M | 4.08M | 8.1M |
| Total Non-current Assets | 38.83M | 10.33M | 52.73M | 102.79M | 50.27M |
| Total Assets | 226.03M | 190.58M | 394.08M | 593.78M | 570.54M |
| Account Payables | 6.69M | 10.19M | 6.16M | 8.6M | 11.26M |
| Short-term Debt | 0 | 20.95M | 46.89M | 0 | 18.45M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 8.1M | 11.53M | 13.76M | 43.18M | 80.84M |
| Total Current Liabilities | 45.52M | 76.69M | 108.07M | 88.3M | 111.54M |
| Long-term Debt | 49.83M | 30.21M | 35.05M | 118.48M | 231.68M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 104.42M | 0 |
| Total Non-current Liabilities | 54.1M | 33.88M | 38.06M | 225.16M | 233.13M |
| Total Liabilities | 99.62M | 110.58M | 146.13M | 313.46M | 344.67M |
| Common Stock | 324K | 390K | 545K | 606K | 640K |
| Retained Earnings | (1.27B) | (1.41B) | (1.6B) | (1.77B) | (1.86B) |
| Accumulated OCI | (173K) | (219K) | 185K | 261K | 269K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 126.42M | 80M | 247.95M | 280.32M | 225.87M |
| Total Debt | 55M | 55.75M | 85.9M | 121.72M | 251.57M |
| Net Debt | 20.13M | (1.09M) | 15.88M | 42.7M | 172.13M |
Geron Corporation
NASDAQ:GERN
Intrinsic Alpha fair value
Locked
Current Price
$0.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.